European Medical Solutions (ALEMS.BR)
EUR 4.9
(1.07%)
EUR 4.9
(1.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -135 Thousand EUR | 92.39% |
| 2022 | -1.77 Million EUR | -1603.39% |
| 2021 | 118 Thousand EUR | 118.68% |
| 2020 | -631.66 Thousand EUR | 96.04% |
| 2019 | -15.95 Million EUR | -24.94% |
| 2018 | -12.76 Million EUR | -6.61% |
| 2017 | -11.97 Million EUR | 2.47% |
| 2016 | -12.27 Million EUR | -60.71% |
| 2015 | -7.64 Million EUR | -76.93% |
| 2014 | -4.31 Million EUR | -87.9% |
| 2013 | -2.29 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | 890 Thousand EUR | 199.89% |
| 2023 FY | -135 Thousand EUR | 92.39% |
| 2023 Q4 | -1.02 Million EUR | -215.17% |
| 2022 Q4 | -891 Thousand EUR | -0.91% |
| 2022 FY | -1.77 Million EUR | -1603.39% |
| 2022 Q2 | -883 Thousand EUR | -120.69% |
| 2021 FY | 118 Thousand EUR | 118.68% |
| 2021 Q4 | 4.26 Million EUR | 1202.78% |
| 2021 Q2 | -387 Thousand EUR | -181.24% |
| 2020 Q2 | -1.1 Million EUR | 86.39% |
| 2020 FY | -631.66 Thousand EUR | 96.04% |
| 2020 Q4 | 476.33 Thousand EUR | 142.99% |
| 2019 Q4 | -8.14 Million EUR | -4.26% |
| 2019 FY | -15.95 Million EUR | -24.94% |
| 2019 Q2 | -7.8 Million EUR | -5.4% |
| 2018 Q4 | -7.4 Million EUR | -38.28% |
| 2018 FY | -12.76 Million EUR | -6.61% |
| 2018 Q2 | -5.35 Million EUR | -3.98% |
| 2017 Q2 | -6.82 Million EUR | -39.74% |
| 2017 Q4 | -5.15 Million EUR | 24.46% |
| 2017 FY | -11.97 Million EUR | 2.47% |
| 2016 Q2 | -7.39 Million EUR | -66.24% |
| 2016 FY | -12.27 Million EUR | -60.71% |
| 2016 Q4 | -4.88 Million EUR | 33.99% |
| 2015 Q2 | -3.19 Million EUR | 0.0% |
| 2015 Q4 | -4.44 Million EUR | -39.42% |
| 2015 FY | -7.64 Million EUR | -76.93% |
| 2014 FY | -4.31 Million EUR | -87.9% |
| 2013 FY | -2.29 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nicox S.A. | -17.5 Million EUR | 99.229% |
| FERMENTALG | -11.8 Million EUR | 98.857% |
| argenx SE | -417.15 Million EUR | 99.968% |
| BioSenic S.A. | -7.04 Million EUR | 98.082% |
| Celyad Oncology SA | -8.45 Million EUR | 98.404% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 99.156% |
| Onward Medical N.V. | -35.46 Million EUR | 99.619% |
| Oxurion NV | -12.11 Million EUR | 98.885% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 99.429% |
| Financière de Tubize SA | -2.14 Million EUR | 93.703% |
| UCB SA | 604 Million EUR | 100.022% |